Dexamethasone NDC 50090-6151

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-6151Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-6151Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-6151-4	50090615104	6 TABLET in 1 BOTTLE (50090-6151-4)Marketed from Oct 5, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dexamethasone
Generic name (nonproprietary): dexamethasone
Active ingredients: Dexamethasone — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 080399
Marketing start: Apr 30, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 50090-6151_cc0444e1-9a6d-4b3c-8a29-047649ffd960SPL ID cc0444e1-9a6d-4b3c-8a29-047649ffd960SPL set ID 89af5591-eebf-44e7-827f-ce3b123123e4RxCUI 197582UNII 7S5I7G3JQL
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090615104 followed by a unit qualifier and the quantity

Package 50090-6151-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 15, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocortico…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 080399

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 080399
Product	Strength	Form · route	Labeler	Product NDC
Dexamethasone	Dexamethasone 4 mg/1	TabletOral	A-S Medication Solutions	50090-6152
Dexamethasone	Dexamethasone 4 mg/1	TabletOral	Prasco Laboratories	66993-730